Baxter to launch new Theranova dialyser

Baxter has announced the launch of its new Theranova dialyser at the latest congress of the European Renal Association and European Dialysis and Transplant Association.

Offering the potential to significantly advance renal care, the dialyser is indicated for the treatment of chronic and acute renal failure by haemodialysis and is designed to extend the range of toxins that can be filtered from the blood.

The permeability and selectivity properties of the new dialyser's membrane has been shown to offer a significantly higher mean overall toxin clearance compared to currently marketed high-flux dialyser offerings.

It has also been demonstrated that the device can clear large uremic toxins that are equivalent to and may exceed those of a haemodiafilter used in high-volume haemodiafiltration mode.

Theranova has received European CE Mark approval, with the commercial rollout of the system planned to take place in 2016 and 2017.

Marcus Schabacker, corporate vice president and chief scientific officer at Baxter, said: "We are introducing an innovative dialyser that has the potential to improve care for the more than two million people globally who rely on haemodialysis. Theranova offers clinicians a more efficient way to deliver haemodialysis without sacrificing performance."